- Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetPlus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold on the company's candidate for ...Endpoints · 2mo ago↗ source
- <![CDATA[OncLive Polls Reveal Picks for Top GI Cancer Abstracts, Areas of Interest at ASCO 2026]]><![CDATA[Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.]]>onclive · 2mo ago↗ source
- M&A isn’t just for big pharma. Mid-size companies are stepping up deal huntsIn what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going shopping. Mid-cap American drugmakers, family-owned pharma gro…